The use of Botulinum Toxin Type A (BoNT-A) has become prevalent not only for therapeutic purposes but also for cosmetic applications. Among healthcare professionals, there has been an increase in BoNT-A administration within familial or friend circles. This rise has corresponded with a notable increase in cases of unilateral blepharoptosis presenting in emergency department admissions. This trend may be attributed to insufficient knowledge and experience regarding the proper dosing of BoNT-A, inadequate understanding of facial anatomy, or anatomical variations of the supraorbital foramen or neurovascular pedicle. While BoNT-A administration for reducing facial wrinkles may appear straightforward for a healthcare professional, a thorough understanding of anatomy and the causes and treatment of blepharoptosis is essential.